Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer’s Drug

Eli Lilly won FDA approval for its Alzheimer’s treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.
The post Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug appeared first on Investor's Business…